Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333216 · ClinicalTrials.gov registry record · Phase 3
Anecortave Acetate Risk-Reduction Trial (AART)
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT00333216 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 24 participants.
The verdict
NCT00333216, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.
Interventions
- DRUG Anecortave Acetate Sterile Suspension, 30 mg/mL
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333216
The ClinicalTrials.gov registry entry for NCT00333216 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Anecortave Acetate Sterile Suspension, 30 mg/mL is the first listed.
NCT00333216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333216 about?
NCT00333216 is a clinical study titled "Anecortave Acetate Risk-Reduction Trial (AART)". The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular deg...
What is the current status of trial NCT00333216?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2005-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00333216?
The interventions under investigation include: Anecortave Acetate Sterile Suspension, 30 mg/mL (DRUG), Anecortave Acetate Vehicle (OTHER), Anecortave Acetate Sterile Suspension, 60 mg/ML (DRUG).
Who is sponsoring clinical trial NCT00333216?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.